



DO YOU WANT TO BE PART OF SOMETHING BIG?

In 2020, Jesse and Meghan Edberg received devastating news that their son William has been diagnosed with a rare neurogenetic disorder called Angelman syndrome (AS). In 2023, Kyle and Alex Laughlin received the same news about their son, Everett.

On August 3, 2024, these two families are coming together to host the **2nd Annual, If Will CAN, We CAN ... Bet on the Trifecta to Beat A.S.**, a fundraising event to benefit the Foundation for Angelman Syndrome Therapeutics (FAST).

This year's event will be held at Canterbury Park in Shakopee, MN, is open to the public with VIP Experience and General Admission ticket options. Last year we had 190 guests and raised over \$50,000 at Surly Brewing Co. in Minneapolis. This year, we have a goal of maxing out attendance at 300 guests and raising \$60,000 towards critical research for AS.

WILL YOU HELP US?


This packet will help you understand how these critical funds will support FAST and the Angelman syndrome community. We are excited to offer a variety of sponsorship opportunities in hopes there is something that fits your level of interest.

Thank you in advance for your consideration!

Sincerely,

will.i.CAN and Mighty Evie

PURCHASE A SPONSORSHIP!



[CLICK HERE](#)



FOUNDATION FOR
ANGELMAN SYNDROME
THERAPEUTICS

t (630) 852-FAST
f (630) 852-3270
t (866) 783-0078
e info@cureangelman.org

PO Box 40307
Austin, TX 78704

Sponsorship Letter

Will.i.CAN and Mighty Evie, along with the Foundation for Angelman Syndrome Therapeutics (FAST) are excited to be hosting a fundraising event with proceeds benefiting the Foundation for Angelman Syndrome Therapeutics. This joint event will raise awareness of Angelman syndrome (AS) and support critical research aiming to one day cure Angelman syndrome and a host of other neurogenetic disorders. This event will be held on **Saturday, August 3rd, 2024 at Canterbury Park in Shakopee, MN.**

Angelman syndrome is a neuro-genetic disorder characterized by developmental delays and multiple neurological issues such as problems with balance and motor coordination and epilepsy. Individuals with AS do not develop functional speech. The seizure disorder in individuals with AS can be difficult to treat and life-threatening. Without a cure, individuals living with AS require life-long care and intensive therapies to develop functional skills and improve their quality of life. Evidence strongly suggests that therapeutic intervention can ameliorate many, if not all, of the symptoms associated with AS.

FAST is the leading Angelman syndrome patient advocacy organization, dedicated to curing AS through the funding of an aggressive research agenda. FAST is committed to assisting individuals living with Angelman syndrome to realize their full potential and quality of life. FAST's goal is to bring practical treatment into current medical practice as quickly as possible. FAST was founded with an urgent mission, to cure Angelman syndrome! Today, with operations in the United States, Australia, the UK, Canada, Italy, France, Spain, Poland and Latin America, FAST is the largest non-governmental funder of Angelman syndrome research, and they take this responsibility seriously.

FAST has set the research agenda for Angelman syndrome from bringing together a multidisciplinary team of more than two-dozen scientists from top research universities and pharmaceutical companies to join forces on a focused path to a cure to ensuring potential therapeutics do not languish in the laboratory. FAST formed the subsidiary, GeneTx Biotherapeutics, in order to develop an antisense oligonucleotide as a potential treatment for Angelman syndrome. FAST and GeneTx advanced this program from a proof of concept in the laboratory into clinical development. FAST was the first rare-disease patient organization to take this approach. GeneTx was the very first company to trial a potentially disease-modifying drug in this patient population. Most recently, Ultragenyx acquired GeneTx to continue to advance development of GTX-102 in Angelman syndrome!

We are seeking sponsorships for the event and in-kind donations for this event. 100% of the net proceeds will go to FAST to support our mission to find a cure for every person living with Angelman syndrome.

Thank you for your consideration,

Meghan Edberg & Lisa Neuwissen

Mother of Will.i.CAN, Grandmother of Mighty Evie

If Will CAN, We CAN ...

Bet on the Trifecta to Beat A.S.



The Foundation for Angelman Syndrome Therapeutics (FAST), in partnership with **Will.i.CAN** & **Mighty Evie**, invites you out for a memorable evening to raise critical research funds to cure Angelman syndrome (AS).

Sat, Aug 3rd, 2024 | Canterbury Park, Shakopee, MN | 4-9pm



Premium Event Packages	Superfecta	Trifecta	Exacta
	\$10,000	\$5,000	\$2,500
Print Recognition			
Recognition in Will.i.CAN e-newsletters	X	X	
Printed logo at event	X	X	X
First right of refusal for 2025	X	X	X
Day of Event			
Complimentary event tickets	10	6	4
Reserved table seating	10 seats	6 seats	4 seats
Name a live race after you/your company	X		
Paddock tour and winner circle experience for your guests	X	X	X
Logo listed on scrolling video screen during event	X	X	X
Company promo item(s) on designated sponsor table	X	X	X
Online Recognition			
Social media – Will.i.CAN Instagram (over 900 followers)	X	X	
Logo on event registration website	X	X	X
Permanent logo presence on Will.i.CAN website	X	X	X

Additional Options:

\$500: General Event Sponsor (multiple available)

Donate to help make this event reach its full potential through a general event sponsorship option. Sponsorship includes:

- Logo listed on scrolling video screen during event
- Logo listed on event registration website + Will.i.CAN website

In-Kind Donations: We welcome any donations to support our event. If you have items, services, and/or experiences you'd like to donate, please email Sue Edberg at susanedberg@hotmail.com

